Psoriasis and Epithelium Derived Cytokines

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Lucia Peterle	+ 897 word(s)	897	2021-12-15 04:05:13	\|
2	format correct	Catherine Yang	Meta information modification	897	2022-01-05 02:04:50	\|

This entry is adapted from the peer-reviewed paper 10.3390/biom11121843

Epithelium-derived cytokines (TSLP, IL-25, IL-33), show an increasing potential for use in target therapy for these patients, and demonstrate a direct link between a generalized inflammatory and oxidative stress status and the human skin. Psoriasis (Pso), characterized by erythematous, scaly patches on the skin and affecting other body districts such as bones and accessory skin structures, presents comorbidities with seemingly unrelated non-skin conditions such as a metabolic syndrome, heart disease and psychiatric disorders.

psoriasis epithelium derived cytokine skin

1. IL-25 and Psoriasis

Xu et al. found that IL-25 levels are increased in the psoriatic skin of mice specimens. In this model, knockout mice for the gene that encodes for IL-25 showed lower amounts of acanthosis, dermal thickness and immune cell infiltration, while injection of IL-25 alone led to the appearance of psoriatic lesions ^[1]. Senra et al. found that IL-25 leads to an accumulation of neutrophils led by macrophages in the site of injection of mice specimens. The psoriasis-like lesions disappeared after five days from the last injection, suggesting their acute role in the development of skin inflammation. The blockade of IL-25 through specific antibodies led to the result of turning off inflammation as well ^[2]. Borowczyk et al. found that IL-22, a cytokine mainly involved in epithelial and stromal cells, can upregulate the production of IL-25, which, as an autocrine effect, leads to proliferation and spikes in metabolic activity in vitro ^[3]. Senra et al. found that, in Pso lesions, levels of IL-25+ cells were higher than those found in control specimen, in particular in the lowermost levels (basal and supra-basal) of the epidermis and activating M2 macrophages to recruit neutrophils where the abscesses of Munro should develop (lowermost strata of epidermis) ^[4].

2. IL-33 and Psoriasis

Chen et al. found that patients with moderate–severe psoriasis have both sera- and intra-epidermal levels of Il-33 higher than healthy controls and, in the same study, an Imiquimod induced Pso model in experimental mice was ameliorated by the injection of IL-33, suggesting the possible anti-inflammatory role of this cytokine ^[5]. Borsky et al. investigated the levels of various alarmins among which IL-33 in the serum of psoriatic patients and they found that its levels were significantly higher than in the controls but did not corelate with the severity of the disease ^[6]. Meephansan et al. proposed two branches of treatment in Pso patients, treated with methotrexate (MTX) or treated with narrow-band ultraviolet rays B (NB-UVB). In the group treated with MTX, levels of IL-33 were lower than before treatment; in contrast, after UVB therapy, levels increased. This led to contrasting results, since the shutting down of IL-33 by MTX led to an amelioration of the skin patches, but UVB therapy alone might produce a direct increase of this particular cytokine as a countereffect, without involving it in the pathogenetic process. The study did not suggest any other interpretations ^[7]. Raimondo et al. demonstrated that IL-33 from psoriatic plaques induces the release of a wide range of osteoclastogenic factors from the skin, such as RANKL, that promote monocyte differentiation in osteoclasts and other osteoclastogenic mediators that could act in a RANKL independent pathway. These results suggest a link between psoriatic cutaneous inflammation and the pathogenesis of psoriatic arthritis (PsA), thus explaining why in most cases Pso anticipates several decays in the onset of PsA ^[8].

3. TSLP and Psoriasis

Gago-Lopez et al. found that TSLP, in psoriasis, plays a wide variety of roles; TSLP enhances cell proliferation (via STAT5 pathway activation) and angiogenesis (via vascular endothelial growth factor production). In a murine model, antibodies directed against TSLP led to a positive response in terms of epidermal thickening and vascularization ^[9]. Tashiro et al., using cultures of HaCaT cells (immortalized keratinocytes), found that TSLP, in hypoxic conditions, presents reduced levels via the inactivation of its production stimulated by TNF-alpha, via HIF2 and HRE mechanisms (two products involved in the skin response to hypoxemia). It is the authors’ suggestion that targeting these two molecules could lead to lower levels of TSLP and the resolution of lesions both in Pso and AD ^[10]. Schaper et al. correlated the levels of TSLP from human skin samples derived from healthy controls, Pso patients and AD patients, noticing that both Pso and AD patients, but mostly Pso patients, presented higher levels of TSLP, especially the inflammation-related isoform rather than the basal one, via histamine release by hyper-active Th2 cells ^[11]. Segawa et al. developed a model using HaCaT cells again, demonstrating that EGFR is transactivated via TSLP by TNF-alpha; it is the author’s suggestion that, since anti-TNF drugs may produce many side effects (such as infections), targeting TSLP instead of TNF-alpha could provide the same results with greater benefits ^[12]. Chen et al., in a 2021 study, matched healthy controls to AD and Pso patients, showing that it is possible to differentiate two separate groups of Pso patients; the most interesting is the “early onset” group, with high levels of Th2 cells and a high TSLP response. The levels of TSLP were higher than those present in AD, suggesting that different subtypes of Pso could benefit from different types of treatment ^[13]. Desmet et al. suggested a novel approach in their study, in which they tried to use RNA interfering molecules, applied topically, to silence the production of several mRNAs among which the mRNA affecting TSLP release. As a result, levels of TSLP dropped, along with the other products, suggesting a possible future treatment for Pso in a 3D model skin ^[14].

References

Xu, M.; Lu, H.; Lee, Y.-H.; Wu, Y.; Liu, K.; Shi, Y.; An, H.; Zhang, J.; Wang, X.; Lai, Y.; et al. An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation. Immunity 2018, 48, 787–798.e4.
Senra, L.; Mylonas, A.; Kavanagh, R.D.; Fallon, P.G.; Conrad, C.; Borowczyk, J.; Wrobel, L.; Kaya, G.; Yawalkar, N.; Boehncke, W.-H.; et al. IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. J. Investig. Dermatol. 2019, 139, 1732–1742.e17.
Borowczyk, J.; Buerger, C.; Tadjrischi, N.; Drukala, J.; Wolnicki, M.; Wnuk, D.; Modarressi, A.; Boehncke, W.-H.; Brembilla, N.C. IL-17E (IL-25) and IL-17A Differentially Affect the Functions of Human Keratinocytes. J. Investig. Dermatol. 2020, 140, 1379–1389.e2.
Senra, L.; Stalder, R.; Martinez, D.A.; Chizzolini, C.; Boehncke, W.-H.; Brembilla, N.C. Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis. J. Investig. Dermatol. 2016, 136, 1970–1980.
Chen, Z.; Hu, Y.; Gong, Y.; Zhang, X.; Cui, L.; Chen, R.; Yu, Y.; Yu, Q.; Chen, Y.; Diao, H.; et al. Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response. Immunology 2020, 160, 382–392.
Borsky, P.; Fiala, Z.; Andrys, C.; Beranek, M.; Hamakova, K.; Malkova, A.; Svadlakova, T.; Krejsek, J.; Palicka, V.; Borska, L.; et al. Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris. Mediat. Inflamm. 2020, 2020, 8465083.
Meephansan, J.; Subpayasarn, U.; Ponnikorn, S.; Chakkavittumrong, P.; Juntongjin, P.; Komine, M.; Ohtsuki, M.; Poovorawan, Y. Methotrexate, but not narrowband ultraviolet B radiation, suppresses interleukin-33 mRNA levels in psoriatic plaques and protein levels in serum of patients with psoriasis. J. Dermatol. 2017, 45, 322–325.
Raimondo, A.; Lembo, S.; Di Caprio, R.; Donnarumma, G.; Monfrecola, G.; Balato, N.; Ayala, F.; Balato, A. Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage. Eur. J. Immunol. 2017, 47, 1062–1074.
López, N.G.; Mellor, L.F.; Megias, D.; Martín-Serrano, G.; Izeta, A.; Jimenez, F.; Wagner, E.F. Role of bulge epidermal stem cells and TSLP signaling in psoriasis. EMBO Mol. Med. 2019, 11, e10697.
Tashiro, N.; Segawa, R.; Tobita, R.; Asakawa, S.; Mizuno, N.; Hiratsuka, M.; Hirasawa, N. Hypoxia inhibits TNF-α-induced TSLP expression in keratinocytes. PLoS ONE 2019, 14, e0224705.
Schaper, K.; Rossbach, K.; Köther, B.; Stark, H.; Kietzmann, M.; Werfel, T.; Gutzmer, R. Stimulation of the histamine 4 receptor upregulates thymic stromal lymphopoietin (TSLP) in human and murine keratinocytes. Pharmacol. Res. 2016, 113, 209–215.
Segawa, R.; Shigeeda, K.; Hatayama, T.; Dong, J.; Mizuno, N.; Moriya, T.; Hiratsuka, M.; Hirasawa, N. EGFR transactivation is involved in TNF-α-induced expression of thymic stromal lymphopoietin in human keratinocyte cell line. J. Dermatol. Sci. 2018, 89, 290–298.
Chen, J.; Li, C.; Li, H.; Yu, H.; Zhang, X.; Yan, M.; Guo, Y.; Yao, Z. Identification of a TH 2-high psoriasis cluster based on skin biomarker analysis in a Chinese psoriasis population. J. Eur. Acad. Derm. Venereol. 2021, 35, 150–158.
Desmet, E.; Van Gele, M.; Grine, L.; Remaut, K.; Lambert, J. Towards the development of a RNAi-based topical treatment for psoriasis: Proof-of-concept in a 3D psoriasis skin model. Exp. Dermatol. 2017, 27, 463–469.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Dermatology

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Lucia Peterle

View Times: 443

Update Date: 05 Jan 2022

Table of Contents

Video Upload Options

Confirm

1. IL-25 and Psoriasis

2. IL-33 and Psoriasis

3. TSLP and Psoriasis

References